Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib with Sintilimab and Chemotherapy in Advanced Non-squamous NSCLC
NCT04956146Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression Free Survival up to 24 months. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04956146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956146.